我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

替罗非班对急性冠脉综合征患者PCI术后MMP-9及IL-6水平的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第2期
页码:
235-237
栏目:
临床研究
出版日期:
2010-12-10

文章信息/Info

Title:
Effect of tirofiban on levels of MMP-9 and IL-6 in acute coronary syndrome patients after percutaneous coronary intervention
作者:
顾晓龙; 龚志华; 邱健
广州军区广州医院心血管内科，广东 广州 510010
Author(s):
GU Xiao-long;  GONG Zhi-hua;  QIU Jian
Department of Cardiology, General Hospital, Guangzhou Military Area Command, Guangzhou 510010, Guangdong, China
关键词:
替罗非班; 急性冠脉综合征; 基质金属蛋白酶-9; 白介素-6
Keywords:
tirofiban;  acute coronary syndrome;  MMP-9;  IL-6
分类号:
R543.3;R654.3
DOI:
-
文献标识码:
A
摘要:
目的: 观察替罗非班对急性冠脉综合征(ACS)患者经皮冠状动脉成形术(PCI)术后基质金属蛋白酶-9(MMP-9)及白介素-6（IL-6）水平的影响。方法： 选择我院2007年2月~2008年12月住院的ACS患者68例，随机分为对照组(n=34)和替罗非班组(n=34)。两组均急诊行PCI术，分别于PCI术前及术后12 h，用ELISA法检测患者血清MMP-9及IL-6的水平。结果： 替罗非班组与对照组相比,PCI术前两组之间MMP-9及IL-6的差异无统计学意义；PCI术后12 h，二者MMP-9的水平［(492±65) vs.(560±82)μg/L］和IL-6的水平［(46.0±7.2) vs.(59.7±8.2)ng/L］差异明显(P<0.05)。结论: 血小板GPⅡb/Ⅲa受体拮抗剂替罗非班能显著降低ACS患者介入术后MMP-9及IL-6的水平，抑制炎症反应，从而对血管具有一定的保护作用。
Abstract:
AIM: To investigate the effect of tirofiban on the levels of MMP-9 and IL-6 in acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI). METHODS: A total of 68 ACS patients in our hospital from February 2007 to December 2008 were randomly divided into tirofiban group (n=34) and control group (n=34). All patients received emergency PCI. Venous blood samples were taken before and 12 h after PCI in both groups and serum samples were analyzed for MMP-9 and IL-6 by ELISA method. RESULTS: No significant difference was observed in the levels of MMP-9 and IL-6 before PCI between the two groups, but the levels of MMP-9 ［(492±65) vs.(560±82) μg/L］ and IL-6 ［(46.0±7.2) vs.(59.7±8.2) ng/L］ in the tirofiban group 12 h after PCI were significantly lower than those in the control group (P<0.05). CONCLUSION: Tirofiban protects the coronary artery by decreasing the levels of MMP-9 and IL-6 after PCI and suppressing inflammatory reaction in ACS patients.

参考文献/References

[1]Rabbani R, Topol EJ. Strategies to achieve coronary arterial plague stabilization［J］. Cardiovasc Res, 1999, 41(2)：402-417．

[2]Ridker PM, Hennekens CH, Buring JE, et al. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women［J］. N Engl J Med, 2000, 342(12):836-843.

[3] Ikeda U, Shimada K. Matrix metalloproteinses and coronary artery diseases［J］. Clin Cardiol, 2003, 26(2):55-59.

[4] Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels［J］. JAMA, 2004, 292(11):1365-1367.

[5]胡大一,马长生. 心脏病学实践2003-新进展与临床案例［M］. 北京: 人民卫生出版社, 2003:23-34.

[6]Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaque: Potential role of matrix-degrading metlloproteinases and implications for plaque rupture［J］. Circulation, 1995, 92(6):1565-1569.

[7]Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metaloproteinase-2 and -9 are elevated in patients with acute coronary syndromes［J］. J Am Coll Cardiol, 1998, 32(2):368-372.

[8]Elmas E, Holzer L, Lang S, et al. Enhanced pro-inflammatory response of mononuclear cells to in vitro LPS-challenge in patients with ventricular fibrillation in the setting of acute myocardial infarction［J］. Cytokine, 2008, 43(2):138-142.

[9]杨新春,徐 立,王乐丰,等. 国产替罗非班对急性心肌梗死患者急诊介入治疗术后冠状动脉血流和心肌灌注影响的研究［J］. 中国循环杂志， 2006, 21(1):4-6.

备注/Memo

备注/Memo:
收稿日期：2010-04-05.作者简介：顾晓龙，硕士Email:guxiaolong3310@163.com
更新日期/Last Update: 2010-12-10